Apricus Biosciences Announces Proposed Public Offering

Apricus Biosciences (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has commenced a public offering of shares of common stock and warrants to purchase shares of common stock.

As quoted in the press release:

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The shares and warrants are being offered pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-221285), that was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on December 7, 2017.

Click here to read the full press release.